Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Angiochem, Inc.
In the third quarter of 2021, medical device company M&A values reached $7.1bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $6.7bn.
Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
Concerned about chronic liver injury, FDA halts development of Geron’s telomerase inhibitor imetelstat, the only drug left standing in Geron’s pipeline, and requests data for patients who discontinued treatment in Geron-sponsored plus non-Geron studies.
- Drug Discovery Tools
- Large Molecule